Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 + SOC in second-line advanced colorectal cancer
NCT05480306Phase 2Completed
- Sponsor
- Leap Therapeutics, Inc.
- Start
- Aug 2022
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of sirexatamab in colorectal cancer (CRC), sponsored by Leap Therapeutics, Inc.. Started Aug 2022; status: completed.
02
Drugs
sirexatamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05480306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480306.